A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Cx 611 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Acronyms SEPCELL
- Sponsors TiGenix
- 12 Aug 2017 This trial has been suspended in Spain.
- 06 Apr 2017 According to a TiGenix media release, data from this trial are expected in 2019.
- 31 Jan 2017 Status changed from planning to recruiting according to a TiGenix media release.